Sitryx nominates SYX-5219 a novel, oral and targeted PKM2 activator for clinical development in atopic dermatitis
10 avr. 2024 07h00 HE
|
Sitryx Therapeutics
Sitryx nominates SYX-5219 a novel, oral and targeted PKM2 activator for clinical development in atopic dermatitis First program from proprietary pipeline of novel immunometabolism-targeting therapies...
Sitryx announces collaboration partner Lilly has commenced a Phase 1 study of SIT-011 for chronic autoimmune and inflammatory diseases
04 janv. 2024 02h00 HE
|
Sitryx Therapeutics
Sitryx announces collaboration partner Lilly has commenced a Phase 1 study of SIT-011 for chronic autoimmune and inflammatory diseases Milestone triggers double-digit million dollar payment to...
Sitryx announces partner Lilly exercises option to SIT-011 for chronic autoimmune and inflammatory diseases
01 nov. 2023 03h00 HE
|
Sitryx Therapeutics
Lilly exercises option to an exclusive worldwide license to develop and commercialize SIT-011, a Phase 1 ready immunometabolism-targeting therapy for chronic autoimmune and inflammatory...
Sitryx further strengthens leadership team with the appointment of Iain Kilty, Ph.D., as Chief Scientific Officer
15 avr. 2021 02h00 HE
|
Sitryx Therapeutics
Sitryx further strengthens leadership team with the appointment of Iain Kilty, Ph.D., as Chief Scientific Officer Oxford, UK – 15 April 2021 – Sitryx (“the Company”), a biopharmaceutical company...
Sitryx appoints Pierre Legault as Chairman of its Board of Directors
24 mars 2021 03h00 HE
|
Sitryx Therapeutics
Sitryx appoints Pierre Legault as Chairman of its Board of Directors Oxford, UK – 24 March 2021 - Sitryx, a biopharmaceutical company focused on regulating cell metabolism to develop...
New biopharmaceutical company Sitryx launches with $30 million fundraising to develop disease modifying therapeutics in immunometabolism
08 oct. 2018 07h00 HE
|
Sitryx Therapeutics
New biopharmaceutical company Sitryx launches with $30 million fundraising to develop disease modifying therapeutics in immunometabolism Fast-emerging area of research with potential to treat severe...
New biopharmaceutical company Sitryx launches with $30 million fundraising to develop disease modifying therapeutics in immunometabolism
08 oct. 2018 02h00 HE
|
Sitryx Therapeutics
New biopharmaceutical company Sitryx launches with $30 million fundraising to develop disease modifying therapeutics in immunometabolism Fast-emerging area of research with potential to treat severe...